ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Japan's Nichi-Iko to sell brand-new drugs in US

TOKYO -- Japan's Nichi-Iko Pharmaceutical seeks to crack the U.S. market with brand-new drugs -- not the generic drugs the company is known for -- as the domestic market is expected to stop growing in the long run.

     The Japanese market for generics is expanding as the government strives to increase the share of these drugs in prescriptions to more than 80% by fiscal 2020. But concerns are strong that drug prices will eventually fall and the market will contract, prompting some generics makers to look overseas.

     Nichi-Iko, the largest generic-drug company in Japan, plans to apply next year for approval from the U.S. Food and Drug Administration to manufacture one brand-new drug. It hopes to gain approval in 2018 and generate annual sales of 3 billion yen ($25.2 million).

     The company believes it will be able to develop drugs more efficiently in the U.S., where finding institutions carrying out clinical trials is relatively easy. It also hopes that brand-new drugs will bring it higher profit margins than generics.

     Nichi-Iko is also preparing U.S. sales of biosimilars. 

     Sawai Pharmaceutical, the No. 2 generics player in Japan, is also eyeing the U.S. market. Unlike Nichi-Iko, Sawai will release generics there. It has applied for FDA approval for its generic version of the Livalo lipid-lowering agent and expects to start selling it as early as March 2018.  

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media